8 hours Ago By ABMN Staff
Allspring Global Investments Holdings LLC raised its stake in shares of Revolution Medicines, Inc. ( NASDAQ:RVMD – Free Report ) by 54.8% in the 4th quarter, according to its most recent disclosure with the SEC.
The firm owned 59,743 shares of the company’s stock after purchasing an additional 21,154 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Revolution Medicines were worth $2,629,000 as of its most recent SEC filing. Other hedge funds have also bought and sold shares of the company.
Quarry LP bought a new stake in Revolution Medicines during the third quarter valued at about $82,000. Values First Advisors Inc. bought a new stake in Revolution Medicines during the third quarter valued at about $93,000.
KBC Group NV grew its holdings in Revolution Medicines by 12.9% during the third quarter. KBC Group NV now owns 3,221 shares of the company’s stock valued at $146,000 after purchasing an additional 368 shares during the period.
Avanza Fonder AB purchased a new position in shares of Revolution Medicines in the fourth quarter valued at about $173,000. Finally, Everence Capital Management Inc. purchased a new position in shares of Revolution Medicines in the fourth quarter valued at about $203,000.
Institutional investors own 94.34% of the company’s stock. Insider Buying and Selling In other Revolution Medicines news, CFO Jack Anders sold 2,635 shares of the company’s stock in a transaction that occurred on Monday, December 16th.
The stock was sold at an average price of $45.40, for a total transaction of $119,629.00.
Following the sale, the chief financial officer now directly owns 96,470 shares in the company, valued at $4,379,738. This represents a 2.66 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is available at this link . Also, insider Mark A. Goldsmith sold 11,714 shares of the company’s stock in a transaction that occurred on Monday, December 16th.
The shares were sold at an average price of $45.40, for a total value of $531,815.60.
Following the sale, the insider now owns 325,056 shares in the company, valued at approximately $14,757,542.40. This trade represents a 3.
48 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last three months, insiders have sold 18,678 shares of company stock worth $847,981.
Corporate insiders own 8.00% of the company’s stock. Revolution Medicines Trading Down 2.
2 % Analyst Ratings Changes Several equities analysts have recently commented on RVMD shares. Guggenheim boosted their price objective on Revolution Medicines from $82.00 to $87.
00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Oppenheimer boosted their price objective on Revolution Medicines from $55.00 to $60.
00 and gave the company an “outperform” rating in a research report on Monday, October 28th. Needham & Company LLC restated a “buy” rating and issued a $68.00 price objective on shares of Revolution Medicines in a research report on Tuesday, December 3rd.
HC Wainwright boosted their price objective on Revolution Medicines from $64.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th.
Finally, JPMorgan Chase & Co. boosted their price objective on Revolution Medicines from $63.00 to $71.
00 and gave the company an “overweight” rating in a research report on Tuesday, December 3rd. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, Revolution Medicines has an average rating of “Buy” and a consensus price target of $66.25. View Our Latest Stock Analysis on RVMD About Revolution Medicines ( Free Report ) Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. See Also Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc.
( NASDAQ:RVMD – Free Report ). Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter .
.
